The occurrence of somatic transformation in germ cell tumour (GCT) is rare, with increased incidence in teratomatous tumours. The aim of this study was to understand the clinical outcomes of patients with metastatic GCT with somatic transformation. A retrospective study was conducted in two tertiary cancer centres in London. Between 1998 and 2016, 30 cases […]
Currently, partial nephrectomy as a nephron-sparing surgery is the standard treatment method of malignant kidney tumors stage T1 in the absence of contraindications. Robotic system is an intuitively convenient platform for performing partial nephrectomy of various degrees of complexity.
San Francisco, CA (UroToday.com) — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of BAVENCIO® (avelumab) in combination with axitinib for the first-line treatment of adult patients […]
To compare long-term functional outcomes after robotic vs. retropubic RP for patients with localized prostate cancer in routine care. “HAROW” was a large German noninterventional health services research study that prospectively evaluated the treatment of patients with localized prostate cancer (≤ T2c). We sent validated questionnaires to 1260 patients who underwent RP to evaluate long-term outcomes. […]
We developed a fast and fully-automated, multi-criteria treatment planning workflow for high dose rate brachytherapy (HDR-BT). In this workflow, the patient-CT with catheter reconstructions and dwell positions are imported from the clinical TPS into a novel system for automated dwell time optimisation. The optimised dwell times are then imported into the clinical TPS. The aims […]
The aim of this study was to investigate the association of prostate-specific antigen (PSA) values on metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) and PSA doubling time (PSADT) < 12 months. This dataset also reflects an update with longer follow-up of our prior publications on the natural history of BRPC in the absence […]
Advanced renal cell carcinoma has historically carried a poor prognosis with very limited treatment options. However, in recent years, the treatment landscape has changed drastically, with many new therapeutic options and improved survival for patients. Novel treatments consist of molecularly targeted agents against the vascular endothelial growth factor (VEGF) pathway as well as the immune […]
Cisplatin is a commonly used chemotherapeutic drug for cancer treatment, but its nephrotoxicity may lead to the deterioration of renal function. Previous work was focused on cisplatin-induced acute kidney disease, whereas the mechanism of chronic kidney disease (CKD) following cisplatin chemotherapy is largely unknown. Here we have characterized the mouse model of chronic kidney defects […]
Urothelial carcinoma can exhibit a wide range of variant morphologies. Many variants present diagnostic challenges and carry clinical implications that inform prognosis and treatment decisions. To provide an overview of the diagnostic, therapeutic, and prognostic significance of histological variants of urothelial carcinoma. A PubMed/MEDLINE-based literature search was conducted using the key terms “urothelial carcinoma”, “variant […]
Current evidence remains equivocal as to whether and how consumption of coffee may be associated with risk of bladder cancer, and potential influence of confounding by smoking on this association is yet to be elucidated. We conducted an updated meta-analysis of prospective studies to address these issues. Relevant studies were identified by searching PubMed and EMBASE […]
